At a glance
ClinicalIndex Comparison RecordN/ACompleted· 439 enrolled
Drug / intervention
Percutaneous coronary interventionprocedure
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Placebo-controlled Trial of Percutaneous Coronary Intervention for the Relief of Stable Angina
In Brief
A clinical study evaluating Percutaneous coronary intervention for Stable Angina. Completed, enrolled 439 participants across 8 sites.
Detailed Summary
ORBITA-2 is a double blinded randomised placebo-controlled trial comparing the effects of coronary angioplasty versus placebo procedure on symptoms of stable angina without background anti-anginal therapy. Follow-up will be at 12 weeks.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsStable Angina
CountriesUnited Kingdom
CollaboratorsBasildon and Thurrock Hospitals NHS FoundationTrust
Timeline
N/ACompletedFinished
20192020202120222023202420252026
Enrollment StartNov 2018
First PostedNov 2018
Primary CompletionSep 2023
TodayJul 2026
First PostedNov 15, 2018
Enrollment StartNov 12, 2018
Primary CompletionSep 6, 2023
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 7.6 years ago
Interventions
Percutaneous coronary interventionprocedure
Percutaneous coronary intervention with drug-eluting stents aiming to achieve complete revascularisation